4.7 Editorial Material

Cefiderocol: the Trojan horse has arrived but will Troy fall?

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Article Immunology

A Randomized, Double-blind, Multicenter Trial Comparing Efficacy and Safety of Imipenem/Cilastatin/Relebactam Versus Piperacillin/Tazobactam in Adults With Hospital-acquired or Ventilator-associated Bacterial Pneumonia (RESTORE-IMI 2 Study)

Ivan Titov et al.

Summary: The study demonstrated that imipenem/cilastatin/relebactam and piperacillin/tazobactam had similar efficacy in treating hospital-acquired/ventilator-associated bacterial pneumonia. Imipenem/cilastatin/relebactam showed favorable safety profile in treating HABP/VABP patients.

CLINICAL INFECTIOUS DISEASES (2021)

Article Immunology

696. Mechanism of Cefiderocol high MIC mutants obtained in non-clinical FoR studies

Akinobu Ito et al.

Open Forum Infectious Diseases (2018)